Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.

Battino D, Biraghi M, Cusi C, Nespolo A, Avanzini G.

Ital J Neurol Sci. 1982 Oct;3(3):197-200.

PMID:
6819250
2.
3.
4.

Gastrointestinal tolerance of divalproex sodium.

Wilder BJ, Karas BJ, Penry JK, Asconape J.

Neurology. 1983 Jun;33(6):808-11.

PMID:
6405304
5.

Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.

Bialer M, Hussein Z, Dubrovsky J, Raz I, Abramsky O.

Isr J Med Sci. 1984 Jan;20(1):46-9.

PMID:
6421770
6.

Rectal administration of sodium valproate in children.

Scanabissi E, Dal Pozzo D, Franzoni E, Galloni C, Mengoli G, Calivà R.

Ital J Neurol Sci. 1984 Jun;5(2):189-93.

PMID:
6432726
7.

Pharmacokinetics of enteric-coated valproic acid.

Albright PS, Bruni J, Suria D.

Ther Drug Monit. 1984;6(1):21-3.

PMID:
6424275
8.

Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.

Anderson P, Elwin CE.

Clin Neuropharmacol. 1985;8(2):156-64.

PMID:
3924399
9.

Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle).

Carrigan PJ, Brinker DR, Cavanaugh JH, Lamm JE, Cloyd JC.

J Clin Pharmacol. 1990 Aug;30(8):743-7.

PMID:
2119396
10.
11.

Chrono impact versus enteric coated valproate in Thai epileptic patients.

Towanabut S, Tiemkao S, Thammasupapong S, Kijjarak R, Arayawichanon A, Poungvarin N, Sirimaharaj S, Chaisewikul R, Asawavichenjinda T, Maneesuk S, Silpakit O.

J Med Assoc Thai. 2005 Nov;88(11):1651-9.

PMID:
16471115
12.

Effect of food on the serum concentration profile of enteric-coated valproic acid.

Fischer JH, Barr AN, Paloucek FP, Dorociak JV, Spunt AL.

Neurology. 1988 Aug;38(8):1319-22.

PMID:
3135514
14.

Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.

Roberts D, Easter D, O'Bryan-Tear G.

Biopharm Drug Dispos. 1996 Mar;17(2):175-82.

PMID:
8907724
15.

Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.

Wangemann M, Retzow A, Vens-Cappell B.

Int J Clin Pharmacol Ther. 1999 Feb;37(2):100-8.

PMID:
10082174
17.

[Comparative study of preparations of sodium and magnesium valproate (VPA) in treatment of patients with epileptic seizures].

Onofrj M, Colangelo U, Malatesta G, Di Giovanni M.

Riv Neurol. 1988 Nov-Dec;58(6):223-30. Italian.

PMID:
3150126
18.

Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.

Garikipati V, Toops DS, Fang Q.

Curr Med Res Opin. 2008 Jul;24(7):1869-76. doi: 10.1185/03007990802122735 .

PMID:
18593524
19.

Meal-dependent absorption of enteric-coated sodium valproate.

Levy RH, Cenraud B, Loiseau P, Akbaraly R, Brachet-Liermain A, Guyot M, Gomeni R, Morselli PL.

Epilepsia. 1980 Jun;21(3):273-80.

PMID:
6769666
20.

Comparison of the gastrointestinal side effects of naproxen formulated as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules.

Aabakken L, Bjørnbeth BA, Hofstad B, Olaussen B, Larsen S, Osnes M.

Scand J Gastroenterol Suppl. 1989;163:65-73.

PMID:
2814364

Supplemental Content

Support Center